# Patient-Trial Match Report

*Generated: 2026-01-05 06:59:40*

## Patient Profile

- **Age**: 55
- **Sex**: Male
- **Cancer Type**: gastric cancer
- **Biomarkers**: HER2 positive, MSI-High

**Clinical Description**:
> 55-year-old male with metastatic gastric adenocarcinoma, HER2-positive (IHC 3+) and MSI-High/dMMR. First-line FOLFOX + trastuzumab + pembrolizumab achieved complete response lasting 16 months. Now recurred with peritoneal carcinomatosis and malignant ascites requiring paracentesis q2 weeks. Declining appetite and early satiety. Lost 8kg over past 2 months. Seeking next-line options that leverage both HER2 targeting and immunotherapy. Mild hypoalbuminemia (3.1). Family history notable for Lynch syndrome (MLH1 mutation in family, patient confirmed carrier).

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 11
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 54
- **LLM scored**: 46

## ðŸŸ¢ HIGH Likelihood (5 trials)

### [NCT04107077](https://clinicaltrials.gov/study/NCT04107077)

**A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases**

- **Sponsor**: University of Chicago
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 55, which is greater than 18
- ECOG performance status is 2
- Histologically confirmed gastric cancer with peritoneal carcinomatosis
- Prior systemic chemotherapy has been completed for more than 4 months
- No brain metastases

**? Uncertainties:**
- Adequate organ and marrow function criteria (leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST/ALT levels, creatinine/GFR levels) are unknown

**Assessment:**
> The patient's disease type matches the trial's indication focusing on gastric cancer with peritoneal metastases. The patient is 55 years old, has an ECOG status of 2, and has completed prior systemic chemotherapy. However, there are uncertainties regarding organ function tests which are critical but not explicitly provided in the profile.

---

### [NCT06503146](https://clinicaltrials.gov/study/NCT06503146)

**18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has gastric cancer, which is included in the trial's conditions studied.
- Patient is 55 years old, which meets the age requirement of >= 18 years.
- Patient's ECOG status is 2, which meets the trial criteria of ECOG <= 2.

**? Uncertainties:**
- Patient's renal function and liver transaminases are not provided, leaving organ function as an uncertainty.

**Assessment:**
> The patient's gastric cancer type matches the conditions studied in the trial. Additionally, the patient meets the age and ECOG status criteria. However, there are uncertainties regarding organ function due to the absence of relevant lab results.

---

### [NCT03740256](https://clinicaltrials.gov/study/NCT03740256)

**A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors**

- **Sponsor**: Baylor College of Medicine
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a histologically confirmed advanced refractory HER2 positive gastric cancer.
- Patient has received prior HER2 targeted therapy (trastuzumab) more than 4 weeks prior to enrollment.
- Patient has an ECOG status of 2, which is acceptable.
- Patient is over 18 years of age and can provide informed consent.

**? Uncertainties:**
- Organ function lab results (e.g., liver and kidney function metrics) are not provided.

**Assessment:**
> The patient has a confirmed diagnosis of HER2 positive gastric cancer, aligning with the trial's focus on HER2 positive solid tumors. The treatment line is appropriate as the patient is not treatment-naive and has progressed after first-line therapy. No conflicts found, though organ function metrics are not available.

---

### [NCT04221893](https://clinicaltrials.gov/study/NCT04221893)

**Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)**

- **Sponsor**: University of California, San Francisco
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- metastatic gastric adenocarcinoma
- progressive disease with prior immunotherapy
- ECOG status 2
- age 55

**? Uncertainties:**
- adequate organ function for radiation therapy and immunotherapy
- evaluation by a radiation oncologist within 28 days of study registration

**Assessment:**
> The patient's cancer type, gastric cancer, aligns with the conditions studied in the trial. The patient has undergone prior therapies, which is acceptable as the trial is for previously treated patients. The ECOG status and age meet the criteria. The lack of brain metastases supports eligibility, but uncertainties around organ function and evaluation timeframe exist.

---

### [NCT04704661](https://clinicaltrials.gov/study/NCT04704661)

**Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced gastric cancer, which is included in the trial conditions.
- Patient is HER2 positive, which is required for eligibility.
- Patient has received prior systemic therapy and is not treatment-naive, aligning with the trial's requirements for previously treated patients.
- ECOG status is 2, which is acceptable for the trial (0-1 preferred, but not explicitly excluding 2).
- Patient has a measurable lesion, indicated by disease recurrence after first-line treatment.

**? Uncertainties:**
- Need verification of organ function labs such as LVEF, renal function, liver function tests, and blood counts as they are not explicitly stated.
- Need confirmation if the patient has a biopsiable lesion and if they can provide an archival tumor sample.

**Assessment:**
> The patient's advanced gastric cancer and HER2 positivity align well with the trial's targeted indications. The patient has undergone prior systemic therapy, making them eligible for this trial recruiting previously treated patients. While there are some uncertainties regarding organ function and biopsy capabilities, the strong overall match with trial criteria elevates the confidence level.

---

## ðŸŸ¡ MEDIUM Likelihood (2 trials)

### [NCT05802056](https://clinicaltrials.gov/study/NCT05802056)

**COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Patient has gastric adenocarcinoma
- Patient has ECOG status 2
- Patient has peritoneal carcinomatosis

**âœ— Potential Conflicts:**
- Previous systemic therapies including pembrolizumab, which may conflict with exclusion criteria regarding prior immune checkpoint inhibitors

**? Uncertainties:**
- Organ function lab results (e.g., hemoglobin, ANC, platelet count, bilirubin, ALT/AST, creatinine clearance)
- Peritoneal Carcinomatosis Index (PCI) not provided

**Assessment:**
> The patient's cancer type matches the trial's indication, but the patient has received prior systemic therapy, which could conflict with eligibility. There are also some uncertainties regarding organ function and PCI results, which need to be clarified.

---

### [NCT04787042](https://clinicaltrials.gov/study/NCT04787042)

**A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies**

- **Sponsor**: Simcha IL-18, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Patient has a histologically confirmed diagnosis of advanced metastatic gastric cancer.
- Patient has MSI-High tumor status.

**âœ— Potential Conflicts:**
- ECOG performance status is 2, while trial requires ECOG 0 or 1.
- Patient has prior therapy with pembrolizumab, which may conflict with eligibility for anti-PD-1 therapy.

**Assessment:**
> The patient's cancer type matches the trial indications since gastric cancer is included in the study for MSI-High tumors. However, the ECOG status of 2 does not meet the trial's requirement of ECOG 0 or 1. Additionally, the patient has previously received pembrolizumab, which could potentially be in conflict with eligibility criteria regarding prior treatment with anti-PD-1 agents.

---

## ðŸŸ  LOW Likelihood (3 trials)

### [NCT06695845](https://clinicaltrials.gov/study/NCT06695845)

**A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)**

- **Sponsor**: Jazz Pharmaceuticals
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 29%

**âœ“ Supporting Factors:**
- Patient has gastric cancer which is a studied condition.
- Patient has HER2 positive status (IHC 3+) which is required.

**âœ— Potential Conflicts:**
- ECOG status is 2 but the trial requires ECOG 0 or 1.
- Patient has received prior HER2-targeted therapy (trastuzumab) which is excluded for Cohort 1.

**? Uncertainties:**
- Adequate organ functions are not explicitly stated.
- Uncertainty whether the patient has measurable lesions.
- Patient's life expectancy is not stated.

**Assessment:**
> The patient matches the cancer type and HER2 status. However, they are excluded due to their ECOG status of 2 and prior HER2-targeted therapy, which does not align with the trial's requirements.

---

### [NCT05753306](https://clinicaltrials.gov/study/NCT05753306)

**A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- ECOG status = 2

**âœ— Potential Conflicts:**
- Patient has malignant ascites at study enrollment which is an exclusion criterion.
- Patient's albumin level (3.1) does not meet the required adequate nutritional status (>= 3.5).

**? Uncertainties:**
- Absolute neutrophil count
- Platelets
- Serum creatinine
- Body Mass Index (BMI)
- Peritoneal Carcinomatosis Index (PCI)

**Assessment:**
> The patient's cancer type matches the trial indication, but the presence of malignant ascites and insufficient serum albumin level conflicts with eligibility. Other standard eligibility criteria need verification but have not been provided.

---

### [NCT04421820](https://clinicaltrials.gov/study/NCT04421820)

**A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours**

- **Sponsor**: Bold Therapeutics, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has gastric cancer, which is included in the trial conditions.

**âœ— Potential Conflicts:**
- ECOG status is 2, while trial eligibility requires ECOG status of 0 or 1.
- Patient is MSI-High, which is excluded for ARM VII of the trial.

**? Uncertainties:**
- Hematologic and organ function details (e.g., ANC, Hgb, platelet count, renal function, bilirubin, transaminases) are not provided.

**Assessment:**
> The patient's gastric cancer matches the trial's conditions; however, the patient's ECOG status is 2, which conflicts with eligibility criteria. Additionally, the patient is MSI-High, which disqualifies them for ARM VII of the trial.

---

## Excluded (89 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02332668](https://clinicaltrials.gov/study/NCT02332668) | Patient age 55 is above maximum age 17 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03607890](https://clinicaltrials.gov/study/NCT03607890) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04114136](https://clinicaltrials.gov/study/NCT04114136) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04383262](https://clinicaltrials.gov/study/NCT04383262) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04486352](https://clinicaltrials.gov/study/NCT04486352) | Trial requires female patients |
| [NCT04774419](https://clinicaltrials.gov/study/NCT04774419) | Trial requires female patients |
| [NCT04802759](https://clinicaltrials.gov/study/NCT04802759) | Trial requires female patients |
| [NCT04852887](https://clinicaltrials.gov/study/NCT04852887) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05035836](https://clinicaltrials.gov/study/NCT05035836) | Trial requires female patients |
| [NCT05142592](https://clinicaltrials.gov/study/NCT05142592) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05200559](https://clinicaltrials.gov/study/NCT05200559) | Trial requires female patients |
| [NCT05239546](https://clinicaltrials.gov/study/NCT05239546) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05256225](https://clinicaltrials.gov/study/NCT05256225) | Trial requires female patients |
| [NCT05477576](https://clinicaltrials.gov/study/NCT05477576) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05559164](https://clinicaltrials.gov/study/NCT05559164) | Trial requires female patients |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05592626](https://clinicaltrials.gov/study/NCT05592626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05855200](https://clinicaltrials.gov/study/NCT05855200) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 34 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Iambic Therapeutics, | Patient's ECOG status is 2, whereas trial requires ECOG 0-1. |
| [NCT04600466](https://clinicaltrials.gov/study/NCT04600466) | The University of Te | Patient has a clinically and genetically confirmed diagnosis of a hereditary cancer syndrome (Lynch syndrome) which is excluded by trial criteria. |
| [NCT03935893](https://clinicaltrials.gov/study/NCT03935893) | Udai Kammula | ECOG status is 2, while trial requires ECOG 0 or 1 |
| [NCT05086692](https://clinicaltrials.gov/study/NCT05086692) | Medicenna Therapeuti | ECOG status (patient's ECOG is 2, trial requires ECOG 0-1) |
| [NCT05438420](https://clinicaltrials.gov/study/NCT05438420) | Qurient Co., Ltd. | ECOG status is 2, which does not meet the inclusion criterion of ECOG 0 or 1. |
| [NCT06047379](https://clinicaltrials.gov/study/NCT06047379) | Neonc Technologies,  | Patient has received prior systemic therapy (FOLFOX, trastuzumab, pembrolizumab), while the trial criteria do not support prior treatments and instead requires treatment-naive patients. |
| [NCT06219941](https://clinicaltrials.gov/study/NCT06219941) | AstraZeneca | ECOG status is 2, while trial requires ECOG 0-1 with no deterioration over the previous 2 weeks. |
| [NCT06062498](https://clinicaltrials.gov/study/NCT06062498) | Northwestern Univers | Patient has gastric cancer, which does not match the trial requirement for ER+/HER2- advanced or metastatic breast cancer. |
| [NCT06710756](https://clinicaltrials.gov/study/NCT06710756) | Perspective Therapeu | ECOG status is 2, which does not meet the requirement of ECOG 0-1. |
| [NCT06790693](https://clinicaltrials.gov/study/NCT06790693) | Hoffmann-La Roche | Patient has gastric cancer while the trial is for breast cancer. |
| [NCT05514717](https://clinicaltrials.gov/study/NCT05514717) | Mersana Therapeutics | ECOG status is 2, but the trial requires ECOG 0 or 1. |
| [NCT06551116](https://clinicaltrials.gov/study/NCT06551116) | Abramson Cancer Cent | Patient has gastric cancer, while the trial is for HER2-positive metastatic breast cancer. |
| [NCT06224673](https://clinicaltrials.gov/study/NCT06224673) | Laura Huppert, MD, B | Patient has gastric cancer, but trial is for HER2-low locally advanced unresectable or metastatic breast cancer. |
| [NCT06671912](https://clinicaltrials.gov/study/NCT06671912) | Alliance for Clinica | The patient has gastric cancer; the trial is for breast cancer. |
| [NCT06126276](https://clinicaltrials.gov/study/NCT06126276) | National Cancer Inst | Patient has gastric cancer; trial is for HER2+ gynecologic cancers and other solid tumors, but excludes breast cancer. |
| [NCT04557969](https://clinicaltrials.gov/study/NCT04557969) | National Cancer Inst | Patient has gastric cancer; trial is specifically for gastrointestinal stromal tumors (GISTs). |
| [NCT02366819](https://clinicaltrials.gov/study/NCT02366819) | University of Chicag | ECOG status is 2, while trial requires ECOG status <= 1 |
| [NCT05488145](https://clinicaltrials.gov/study/NCT05488145) | Emory University | Patient has gastric cancer, but trial is for breast cancer. |
| [NCT04862663](https://clinicaltrials.gov/study/NCT04862663) | AstraZeneca | Patient has gastric cancer while the trial is for breast cancer. |
| [NCT05095207](https://clinicaltrials.gov/study/NCT05095207) | Icahn School of Medi | Patient has gastric cancer, while the trial is for HER2-negative breast cancer. |
| ... | ... | *and 15 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| MSI-High | manual | 1.0 |
| gastric cancer | manual | 1.0 |
| HER2 positive gastric cancer | manual | 1.0 |
| MSI-High gastric cancer | manual | 1.0 |
| HER2 positive gastric adenocarcinoma | llm | 0.9 |
| stomach cancer | llm | 0.8 |
| gastric adenocarcinoma | llm | 0.8 |
| HER2 | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
